The objective of this study is to compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK)
Neurotrophic Keratopathy
The objective of this study is to compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK)
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
-
Harvard Eye Associates, Laguna Hills, California, United States, 92653
Loma Linda University Eye Institute, Loma Linda, California, United States, 92354
Nvision Clinical Research, LLC., Los Angeles, California, United States, 90013
Dr. Shultz and Dr. Chan, Northridge, California, United States, 91325
Retina Consultants of Southern Colorado, Colorado Springs, Colorado, United States, 80909
Advance Vision Research Institute, Longmont, Colorado, United States, 80503
Connecticut Eye Consultants, P.C. Danbury Eye Physicians & Surgeons, Danbury, Connecticut, United States, 06810
University of Miami, Coral Gables, Florida, United States, 33146
University of South Florida, Ophthalmolgoy, Tampa, Florida, United States, 33612
Thomas Eye Group, P.C., Sandy Springs, Georgia, United States, 30328
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
ReGenTree, LLC,
2024-11-30